US2020016233A1PendingUtilityA1

Molecular Composition for Enhancing and Rejuvenating Maintenance and Repair of Mammalian Tissues

59
Assignee: UNIV CALIFORNIAPriority: Aug 12, 2014Filed: Feb 25, 2019Published: Jan 16, 2020
Est. expiryAug 12, 2034(~8 yrs left)· nominal 20-yr term from priority
Inventors:Irina M. ConboyDavid V. SchafferHanadie YousefMichael J. ConboyWendy CousinChristian Elabd
A61K 38/1841A61K 38/095C12N 2501/30C12N 2501/999A61K 31/444C12N 5/0658A61K 31/536C12N 2501/727C12N 5/0623G01N 33/502
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods, pharmaceutical compositions, and kits are provided for treating a subject with an effective amount of an oxytocin receptor (OXTR) agonist and an effective amount of an ALK5 antagonist. In certain aspects, the OXTR agonist may be oxytocin or an oxytocin analog (e.g., a small molecule). The ALK 5 antagonist may be a small molecule, such as 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, LY2157299, A 83-01, D 4476, GW 788388, LY 364947, RepSox, SB 431542, SB 505124, SB 525334, or SD 208. In certain aspects, the amounts of the OXTR agonist and ALK5 antagonist may be sufficient to induce muscle regeneration and/or neural cell regeneration in the subject.

Claims

exact text as granted — not AI-modified
1 . - 37 . (canceled) 
     
     
         38 . A composition comprising:
 an OXTR agonist;   an ALK5 antagonist; and   a pharmaceutically acceptable excipient.   
     
     
         39 . The composition of  claim 38 , wherein the amount of the OXTR agonist is in the range of 7.5 nM-30 nM. 
     
     
         40 . The composition of  claim 38 , wherein the amount of the ALK5 antagonist is in the range of 0.05 μM-3 μM. 
     
     
         41 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:50. 
     
     
         42 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 50:1. 
     
     
         43 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:40. 
     
     
         44 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:30. 
     
     
         45 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 40:1. 
     
     
         46 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:25. 
     
     
         47 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 25:1. 
     
     
         48 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:10. 
     
     
         49 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 10:1. 
     
     
         50 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:5. 
     
     
         51 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 5:1. 
     
     
         52 . The composition of  claim 38 , wherein the ratio of the OXTR agonist to the ALK5 antagonist is 1:1. 
     
     
         53 . The composition of  claim 38 , wherein the OXTR agonist is oxytocin. 
     
     
         54 . The composition of  claim 38 , wherein the ALK5 antagonist is 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine. 
     
     
         55 . Use of an OXTR agonist and an ALK5 antagonist for enhancing proliferation of a somatic cell, the use comprising contacting a somatic cell with oxytocin receptor (OXTR) agonist and ALK5 antagonist,
 wherein the contacting is with an amount of the OXTR agonist and ALK5 antagonist effective to enhance proliferation of the somatic cell.   
     
     
         56 .- 72 . (canceled)

Join the waitlist — get patent alerts

Track US2020016233A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.